Brochure
18 Oct 2024

Rokote Laboratories signs an agreement with 3PBIOVIAN for GMP manufacturing of a

PDF 506 kB

Rokote Laboratories Finland Ltd. has selected 3PBIOVIAN as their CDMO partner for GMP manufacturing of adenovirus type 5 (Ad5) vector-based candidate.

Content provided by our supplier

3PBIOVIAN

  • Country/Region:
    Spain
  • On CPHI since:
    2015
  • Certificates:
    3
  • Employees:
    500 - 999
Company types
CMO/CDMO
Contract Service
Manufacturer/Innovator
Primary activities
Animal Health
API Producer
Biopharmaceutical
Contract Manufacturer

Other Content from 3PBIOVIAN (9)

  • News Rokote Laboratories signs an agreement with 3PBIOVIAN for GMP manufacturing of adenovirus vector-based COVID-19 vaccine

    Rokote Laboratories Finland Ltd. has selected 3PBIOVIAN as their CDMO partner for GMP manufacturing of adenovirus type 5 (Ad5) vector-based candidate expressing a modified spike protein of severe acute respiratory coronavirus 2 (SARS-CoV-2).

  • Brochure 3P Biopharmaceuticals and Biovian join forces to create 3PBIOVIAN, a leading pa

    Biovian and 3P Biopharmaceuticals (“3P”), two leading biologics Contract Development and Manufacturing Organizations (CDMOs), announced their combination.
  • News 3P Biopharmaceuticals and Biovian join forces to create 3PBIOVIAN, a leading pan-European biologics CDMO

    Paris, February 1, 2024 - Biovian and 3P Biopharmaceuticals (“3P”), two leading biologics Contract Development and Manufacturing Organizations (CDMOs), announced today their combination to establish a new pan-European leader in their field. Backed by their common shareholder, Keensight Capital, one of the leading private equity funds dedicated to pan-European Growth Buyout[[1]] investments, the combination of Biovian and 3P further extends the group’s value proposition to address complex customer needs across the entire development cycle.

    [1] Growth Buyout: investment in profitable, private companies experiencing strong growth, in minority or majority positions, with or without leverage, using a flexible approach tailored to the needs of individual entrepreneurs, in order to finance organic growth projects, acquisition strategies or provide historic shareholders with liquidity.

  • Brochure AAVion flyer

    From plasmid to vial, our proprietary AAVion® platformpropels your path to clinical success.
  • Brochure Analytical Services 3PBIOVIAN Flyer

    With decades of experience, specialized know-how, and state-of-the-art facilities,we’re the CDMO partner you can count on for biologics and advanced therapies.
  • Brochure Mammalian 3PBIOVIAN Flyer

    Choose our Mammalian CDMO services toproduce your recombinant proteins and antibodies.
  • Brochure Microbial 3PBIOVIAN Flyer

    Choose our Microbial CDMO servicesfor recombinant protein production using bacterialand yeast cell lines.
  • Brochure pDNA 3PBIOVIAN Flyer

    Plasmid DNA (pDNA) is a critical raw material for viral vectorproduction, such as adeno-associated virus (AAV), as well asnon-viral gene therapy, and DNA or mRNA vaccine development. Whether youneed research-grade (RG), high-quality (HQ), or GMP-grade pDNA, we deliverthe experience and quality your project needs.
  • Brochure Viral Analytics Services

    We understand that time, cost, and quality are not justpriorities - they are critical to your success. That’s whywe are committed to delivering tailored, flexible, andcost-effective solutions that meet your needs, withoutcompromise.